KF17837	kf17837	O	O
:	:	O	O
a	a	O	O
novel	novel	O	O
selective	selective	O	O
adenosine	adenosine	S_chemical	O
A2A	a2a	O	O
receptor	receptor	O	O
antagonist	antagonist	O	O
with	with	O	O
anticataleptic	anticataleptic	O	O
activity	activity	O	O
.	.	O	O

KF17837	kf17837	O	O
is	is	O	O
a	a	O	O
novel	novel	O	O
selective	selective	O	O
adenosine	adenosine	S_chemical	O
A2A	a2a	O	O
receptor	receptor	O	O
antagonist	antagonist	O	O
.	.	O	O

Oral	oral	O	O
administration	administration	O	O
of	of	O	O
KF17837	kf17837	O	O
(	(	O	O
2.5	2.5	O	O
,	,	O	O
10.0	10.0	O	O
and	and	O	O
30.0	30.0	O	O
mg/kg	mg/kg	O	O
)	)	O	O
significantly	significantly	O	O
ameliorated	ameliorated	O	O
the	the	O	O
cataleptic	cataleptic	O	O
responses	responses	O	O
induced	induced	O	O
by	by	O	O
intracerebroventricular	intracerebroventricular	O	O
administration	administration	O	O
of	of	O	O
an	an	O	O
adenosine	adenosine	S_chemical	O
A2A	a2a	O	O
receptor	receptor	O	O
agonist	agonist	O	O
,	,	O	O
CGS	cgs	O	O
21680	21680	O	O
(	(	O	O
10	10	O	O
micrograms	micrograms	O	O
)	)	O	O
,	,	O	O
in	in	O	O
a	a	O	O
dose-dependent	dose-dependent	O	O
manner	manner	O	O
.	.	O	O

KF17837	kf17837	O	O
also	also	O	O
reduced	reduced	O	O
the	the	O	O
catalepsy	catalepsy	O	S_disease
induced	induced	O	O
by	by	O	O
haloperidol	haloperidol	S_chemical	O
(	(	O	O
1	1	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
and	and	O	O
by	by	O	O
reserpine	reserpine	S_chemical	O
(	(	O	O
5	5	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
.	.	O	O

These	these	O	O
anticataleptic	anticataleptic	O	O
effects	effects	O	O
were	were	O	O
exhibited	exhibited	O	O
dose	dose	O	O
dependently	dependently	O	O
at	at	O	O
doses	doses	O	O
from	from	O	O
0.625	0.625	O	O
and	and	O	O
2.5	2.5	O	O
mg/kg	mg/kg	O	O
p.o	p.o	O	O
.	.	O	O
,	,	O	O
respectively	respectively	O	O
.	.	O	O

Moreover	moreover	O	O
,	,	O	O
KF17837	kf17837	O	O
(	(	O	O
0.625	0.625	O	O
mg/kg	mg/kg	O	O
p.o	p.o	O	O
.	.	O	O
)	)	O	O
potentiated	potentiated	O	O
the	the	O	O
anticataleptic	anticataleptic	O	O
effects	effects	O	O
of	of	O	O
a	a	O	O
subthreshold	subthreshold	S_chemical	O
dose	dose	O	O
of	of	O	O
L-3,4-dihydroxyphenylalanine	l-3,4-dihydroxyphenylalanine	S_chemical	O
(	(	O	O
L-DOPA	l-dopa	O	O
;	;	O	O
25	25	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
plus	plus	O	O
benserazide	benserazide	S_chemical	O
(	(	O	O
6.25	6.25	O	O
mg/kg	mg/kg	O	O
i.p	i.p	O	O
.	.	O	O
)	)	O	O
.	.	O	O

These	these	O	O
results	results	O	O
suggested	suggested	O	O
that	that	O	O
KF17837	kf17837	O	O
is	is	O	O
a	a	O	O
centrally	centrally	O	O
active	active	O	O
adenosine	adenosine	S_chemical	O
A2A	a2a	O	O
receptor	receptor	O	O
antagonist	antagonist	O	O
and	and	O	O
that	that	O	O
the	the	O	O
dopaminergic	dopaminergic	O	S_disease
function	function	O	O
of	of	O	O
the	the	O	O
nigrostriatal	nigrostriatal	O	O
pathway	pathway	O	O
is	is	O	O
potentiated	potentiated	O	O
by	by	O	O
adenosine	adenosine	S_chemical	O
A2A	a2a	O	O
receptor	receptor	O	O
antagonists	antagonists	O	O
.	.	O	O

Furthermore	furthermore	O	O
,	,	O	O
KF17837	kf17837	O	O
may	may	O	O
be	be	O	O
a	a	O	O
useful	useful	O	O
drug	drug	O	O
in	in	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
parkinsonism	parkinsonism	O	S_disease
.	.	O	O

